Pay to delay is strategy of pharmaceutical companies whereby the owners of a drug patent pay (bribe?) generic manufactureres to not market generic competition for their patented agent.
“lucrative settlements between generic and branded drugmakers have flourished. According to the FTC, nearly half of all settlements between 2006 and 2007 involved payments to keep low-cost drugs off the market.”
Imagine, our non-system facilitates keeping drug costs high. What a system.
Powered by Zoundry Raven
Medicynic 